Zobrazeno 1 - 10
of 721
pro vyhledávání: '"Intra-tumor"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Osteosarcoma (OS) is a heterogeneous malignant spindle cell tumor that is aggressive and has a poor prognosis. Although combining surgery and chemotherapy has significantly improved patient outcomes, the prognosis for OS patients with metast
Externí odkaz:
https://doaj.org/article/419e618dc8454f3eb606f5b9fdc565a4
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Background The tumor microenvironment is profoundly heterogeneous particularly when comparing sites of metastases. Establishing the extent of this heterogeneity may provide guidance on how best to design lipid-based drug delivery systems to
Externí odkaz:
https://doaj.org/article/9192e449a6724fde9d21e119bf73a0bd
Publikováno v:
BMC Genomics, Vol 25, Iss 1, Pp 1-14 (2024)
Abstract Background Accurately deciphering clonal copy number substructure can provide insights into the evolutionary mechanism of cancer, and clustering single-cell copy number profiles has become an effective means to unmask intra-tumor heterogenei
Externí odkaz:
https://doaj.org/article/53842a8ef2cb4ffaad7b603400b80f68
Autor:
Karl F. B. Payne, Peter Brotherwood, Harini Suriyanarayanan, Jill M. Brooks, Nikolaos Batis, Andrew D. Beggs, Deena M. A. Gendoo, Hisham Mehanna, Paul Nankivell
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundAs circulating tumour DNA (ctDNA) liquid biopsy analysis is increasingly incorporated into modern oncological practice, establishing the impact of genomic intra-tumoural heterogeneity (ITH) upon data output is paramount. Despite advances in
Externí odkaz:
https://doaj.org/article/e05145d79eb243d7a8953e7b92d45ddb
Publikováno v:
Genome Biology, Vol 24, Iss 1, Pp 1-23 (2023)
Abstract A tumor contains a diverse collection of somatic mutations that reflect its past evolutionary history and that range in scale from single nucleotide variants (SNVs) to large-scale copy-number aberrations (CNAs). However, no current single-ce
Externí odkaz:
https://doaj.org/article/5435dde5ac3e4bb780badd7e110b055f
Autor:
Cristina Contini, Barbara Manconi, Alessandra Olianas, Giulia Guadalupi, Alessandra Schirru, Luigi Zorcolo, Massimo Castagnola, Irene Messana, Gavino Faa, Giacomo Diaz, Tiziana Cabras
Publikováno v:
Cells, Vol 13, Iss 16, p 1311 (2024)
Colorectal cancer (CRC) is a frequent, worldwide tumor described for its huge complexity, including inter-/intra-heterogeneity and tumor microenvironment (TME) variability. Intra-tumor heterogeneity and its connections with metabolic reprogramming an
Externí odkaz:
https://doaj.org/article/1d0e0d32178540e5b4c651ccb03c8f00
Autor:
Menghan Wang, Yanqi Xie, Jinpeng Liu, Austin Li, Li Chen, Arnold Stromberg, Susanne M. Arnold, Chunming Liu, Chi Wang
Publikováno v:
Cancers, Vol 16, Iss 13, p 2488 (2024)
The development of cancer involves the accumulation of somatic mutations in several essential biological pathways. Delineating the temporal order of pathway mutations during tumorigenesis is crucial for comprehending the biological mechanisms underly
Externí odkaz:
https://doaj.org/article/76e21588c0744025a9ec8b0248ffc2c4
Publikováno v:
Translational Oncology, Vol 40, Iss , Pp 101855- (2024)
Background: Chemotherapy resistance is the main cause of ovarian cancer progression and even death. However, there are no clear indicators for predicting the risk of drug resistance in patients. Intra-tumor heterogeneity (ITH) is one of the character
Externí odkaz:
https://doaj.org/article/cf7d6e2f82a6482da3173b8e14bb470f
Publikováno v:
BMC Research Notes, Vol 16, Iss 1, Pp 1-8 (2023)
Abstract Objective Tumors are heterogeneous three-dimensional masses populated by numerous cell types, including distinct sub-clones of cancerous cells. Various sub-clones within the same tumor mass may respond differently to cancer treatment, and in
Externí odkaz:
https://doaj.org/article/176a176885cb4c47a1de5292eb97ff36
Autor:
Louis Y. El Khoury, Xiaoyu Pan, Ryan A. Hlady, Ryan T. Wagner, Shafiq Shaikh, Liguo Wang, Mitchell R. Humphreys, Erik P. Castle, Melissa L. Stanton, Thai H. Ho, Keith D. Robertson
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-20 (2023)
Abstract Background Clear cell renal cell cancer (ccRCC), the 8th leading cause of cancer-related death in the US, is challenging to treat due to high level intratumoral heterogeneity (ITH) and the paucity of druggable driver mutations. CcRCC is unus
Externí odkaz:
https://doaj.org/article/584e5c915d604bcbbb2b14be31291f9d